on NOVACYT (EPA:ALNOV)
Novacyt anticipates significant growth for 2024
Novacyt, a leading molecular diagnostics company, has announced its preliminary results for 2024. The group's unaudited turnover is estimated at £19.6 million, representing a notable increase of 85% compared to 2023. This increase is mainly attributed to the integration of Yourgene Health.
Yourgene's results, however, show a decline in revenue from non-invasive prenatal screening services. Despite this, the company is showing growth in reproductive health and Ranger consumables. Primer Design has helped stabilize revenue.
Novacyt continues to position itself in the market through the development of new analytical capabilities and new products, while streamlining its operations. The company plans to publish its annual results in April 2025.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NOVACYT news